tqxz2rz2 | Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/tqxz2rz2_hasAnnotation_C0037088>
?:creator	<https://research.tib.eu/covid-19/entity/de_Miranda_Santos%2C_Isabel_Kinney_Ferreira%3B_de_Barros_Cardoso%2C_Cristina_Ribeiro>
?:doi	10.1016/j.clim.2020.108618
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.clim.2020.108618>
?:journal	Clin_Immunol
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/dbb019028fa8a69db9c9498ad21249f84e30e33a.json
?:pmc_json_files	document_parses/pmc_json/PMC7588791.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7588791>
?:pmid	<https://research.tib.eu/covid-19/entity/33127564.0>
?:pmid	33127564.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/tqxz2rz2_HAS_C0009506_ASSOCIATED_WITH_C5203670>
?:sha_id	<https://research.tib.eu/covid-19/entity/dbb019028fa8a69db9c9498ad21249f84e30e33a>
?:source	Elsevier; Medline; PMC
?:title	Commentary on “Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al.
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-27

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/tqxz2rz2>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/tqxz2rz2>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all